Review of preclinical NMN evidence for ovarian health and aging
This review of preclinical studies reports that NMN supplementation in animal models improved mitochondrial function and oocyte quality and was associated with delayed ovarian senescence; human efficacy and safety remain unestablished. [1]
Automatic summary · not editorially reviewed
The key findings
The review evaluates preclinical evidence on whether NMN can attenuate ovarian aging, improve follicular reserve and restore endocrine function. [1]
In animal studies, NMN supplementation enhanced mitochondrial function, reduced oxidative stress and modulated sirtuin activity in ovarian tissue. [1]
Findings in rodent models are encouraging, but clinical translation remains limited and human studies are needed. [1]
The source at a glance
- Study type / format
- Comprehensive literature review of preclinical evidence (abstract)
- Population / context
- Ovarian tissue and animal models of ovarian aging, chemotherapy-induced ovarian insufficiency and age-related ovarian decline
- Summary based on
- Study abstract
- Original publication
- August 4, 2026
Review scope: NMN and ovarian aging in preclinical models
The abstract describes a literature review that critically evaluates preclinical evidence on nicotinamide mononucleotide (NMN), a precursor of nicotinamide adenine dinucleotide (NAD+). The focus is whether NMN can attenuate ovarian aging, improve follicular reserve and restore endocrine function. The review also summarizes molecular pathways influenced by NMN, including the NAD+/sirtuin-1 (SIRT1) axis.
Supporting source [1]
Animal findings: mitochondria, oocytes and hormonal profiles
According to the abstract, animal studies showed that NMN supplementation enhanced mitochondrial function, reduced oxidative stress and modulated sirtuin activity in ovarian tissue. These effects contributed to improved oocyte quality, delayed ovarian senescence and prolonged reproductive lifespan. In models of chemotherapy-induced ovarian insufficiency and age-related ovarian decline, NMN administration was associated with increased folliculogenesis and normalization of hormonal profiles. Anti-inflammatory and anti-apoptotic properties are described as suggesting possible applications in premature ovarian insufficiency and polycystic ovary syndrome.
Supporting source [1]
Translation gap: rodent evidence, no human efficacy data
The abstract states that findings in rodent models are encouraging but that clinical translation remains limited. It highlights important gaps in current knowledge and calls for well-designed human studies to establish efficacy and safety in reproductive medicine. The review therefore describes therapeutic potential rather than proven human benefit.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. All reported effects come from preclinical animal models, and the abstract provides no human efficacy or safety data.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Kang I, Lee J. · europepmc.org · August 4, 2026